Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease
-
Published:2018-04-24
Issue:1
Volume:9
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Emdin Connor A.ORCID, Khera Amit V., Chaffin MarkORCID, Klarin Derek, Natarajan Pradeep, Aragam Krishna, Haas Mary, Bick Alexander, Zekavat Seyedeh M., Nomura Akihiro, Ardissino Diego, Wilson James G., Schunkert Heribert, McPherson Ruth, Watkins Hugh, Elosua Roberto, Bown Matthew J., Samani Nilesh J., Baber Usman, Erdmann JeanetteORCID, Gupta Namrata, Danesh John, Chasman Daniel, Ridker Paul, Denny Joshua, Bastarache Lisa, Lichtman Judith H., D’Onofrio Gail, Mattera Jennifer, Spertus John A., Sheu Wayne H.-H., Taylor Kent D., Psaty Bruce M., Rich Stephen S., Post Wendy, Rotter Jerome I., Chen Yii-Der Ida, Krumholz Harlan, Saleheen DanishORCID, Gabriel Stacey, Kathiresan SekarORCID
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference40 articles.
1. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: illuminating the dark road from association to function. Am. J. Hum. Genet. 93, 779–797 (2013). 2. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154–156 (2003). 3. Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006). 4. Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713-1722 (2017). 5. Dewey, F. E. et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med. 377, 211–221 (2017).
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|